Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly.

ABSTRACT: Recent approval of chimeric antigen receptor (CAR) T cell therapy by the European Medicines Agency (EMA)/Federal and Drug Administration (FDA) and the remarkable results of CAR T clinical trials illustrate the curative potential of this therapy. While CARs against a multitude of different antigens are being developed and tested (pre)clinically, there is still a need for optimization. The use of single-chain variable fragments (scFvs) as targeting moieties hampers the quick generation of functional CARs and could potentially limit the efficacy. Instead, nanobodies may largely circumvent these difficulties. We used an available nanobody library generated after immunization of llamas against Cluster of Differentiation (CD) 20 through DNA vaccination or against the ectodomain of CD33 using sol

SUBMITTER: De Munter S 

PROVIDER: S-EPMC7037261 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature